Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Limosilactobacillus reuteri - BioGaia/Infant Bacterial Therapeutics

Next Previous
Drug Profile

Limosilactobacillus reuteri - BioGaia/Infant Bacterial Therapeutics

Alternative Names: Apylori Probiotic Capsules; BioGaia ProTectis; IBP 9414; Lactobacillus reuteri; Lactobacillus reuteri ATCC 55730; Lactobacillus reuteri DSM 17938; Lactobacillus reuteri Protectis; NEC therapy - BioGaia

Latest Information Update: 10 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioGaia; Infant Bacterial Therapeutics
  • Class Anti-inflammatories; Antihyperglycaemics; Bacteria; Laxatives; Probiotics
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Necrotising enterocolitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastrointestinal disorders
  • Phase III Necrotising enterocolitis
  • Phase II Constipation; Type 2 diabetes mellitus

Most Recent Events

  • 10 Mar 2025 Infant Bacterial Therapeutics plans for launch for Lactobacillus reuteri for Necrotising enterocolitis
  • 13 Feb 2025 BioGaia intends to seek marketing approval for Lactobacillus reuteri for Necrotising enterocolitis in USA in 2025
  • 28 Dec 2024 No recent reports of development identified for clinical-Phase-Unknown development in Gastrointestinal-disorders(In volunteers) in Sweden (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top